Investor Presentaiton
INO-4800 Demonstrates Durable Efficacy, Safety;
Only COVID-19 Vaccine With No Adverse Events > Grade 1
TRIALS: INO-4800
Human
Clinical Study:
Interim findings
(Week 6 efficacy and
Week 8 safety)
•
Protect against SARS-CoV2 virus that causes COVID-19
Target Spike protein
Phase 1 study
(Initial 2 cohorts reported)
100% (38 out of 38) of trial
participants demonstrated
overall immunological
responses through week 6
Non-Human
Primate (NHP) Study:
17-week findings
(13 weeks after
2nd dose)
Challenge study
Durable antibody and T cell
responses for >4 months
after initial dose
Demonstrated binding and
neutralizing antibodies and
T cell immune responses
Memory T and B cell
responses reduced viral
loads, faster clearance in
lungs, nasal passages
40 healthy volunteers age 18-50
X40 1 mg and 2 mg cohorts, 2 doses (Weeks 0 and 4)
x10
Safe and well tolerated,
no SAEs through Week 8
Trial expanded with
older participants, 18
and older and added
dose arm of 0.5 mg
5 rhesus macaques received INO-4800, 5 received placebo
2 doses (Weeks 0 and 4)
Challenge with SARS-CoV-2 (Week 17)
Neutralizing antibodies
against early virus and
dominant G614 mutant
variant
No antibody-dependent
enhanced disease events
15
INOVIO
POWERING DNA MEDICINESView entire presentation